ライフサイエンスコーパス: diastolic dysfunction

1 /or reduced global longitudinal strain, with diastolic dysfunction).

2 apeutic applications in cardiac fibrosis and diastolic dysfunction.

3 osolic calcium reuptake kinetics, indicating diastolic dysfunction.

4 ion and contribution to cardiac fibrosis and diastolic dysfunction.

5 f detyrosination as a therapeutic target for diastolic dysfunction.

6 rated rats and aortic-banded rats exhibiting diastolic dysfunction.

7 patients with AD present with an anticipated diastolic dysfunction.

8 d that inhibiting PDE9a activity ameliorates diastolic dysfunction.

9 reasing the compliance of titin in mice with diastolic dysfunction.

10 l or unrecognized, with a high prevalence of diastolic dysfunction.

11 LV hypertrophy and subclinical markers of LV diastolic dysfunction.

12 n, increases calcium sensitivity, and causes diastolic dysfunction.

13 asis and cellular remodeling, which leads to diastolic dysfunction.

14 ciated with left ventricular hypertrophy and diastolic dysfunction.

15 lthough MS seems to be associated with worse diastolic dysfunction.

16 chanical mechanism which may partly underlie diastolic dysfunction.

17 r hypertrophy, left ventricular systolic and diastolic dysfunction.

18 iated with cardiac hypertrophy, fibrosis and diastolic dysfunction.

19 It appears to be associated with diastolic dysfunction.

20 r impaired fluid dynamics may be a source of diastolic dysfunction.

21 on in thin-filament HCM, reflecting profound diastolic dysfunction.

22 associated with echocardiographic indexes of diastolic dysfunction.

23 s, such as increased myocardial stiffness or diastolic dysfunction.

24 herefore likely to be a major contributor to diastolic dysfunction.

25 ssociated with echocardiographic evidence of diastolic dysfunction.

26 RDN reduces BP, HR, and LV mass and improves diastolic dysfunction.

27 entricular ejection fraction and evidence of diastolic dysfunction.

28 Ca(2+) sensitivity, severe hypertrophy, and diastolic dysfunction.

29 significantly lower values in patients with diastolic dysfunction.

30 ertension, left ventricular hypertrophy, and diastolic dysfunction.

31 ejection fraction (EF) group in MIS-C showed diastolic dysfunction.

32 SCM and LAD MI show severe diastolic dysfunction.

33 from mice with metabolic syndrome-associated diastolic dysfunction.

34 tolerance, a phenotype often associated with diastolic dysfunction.

35 post ASO and are likely to contribute to LV diastolic dysfunction.

36 ar function accompanied by both systolic and diastolic dysfunction.

37 ar heart disease often have left ventricular diastolic dysfunction.

38 in post-myocardial infarction patients with diastolic dysfunction.

39 e (BNP), and echocardiographic parameters of diastolic dysfunction.

40 pporting a titin-based mechanism for in vivo diastolic dysfunction.

41 ables as a first step in the detection of LV diastolic dysfunction.

42 hasome, and leads to substantial reversal of diastolic dysfunction.

43 le volumes but not with ejection fraction or diastolic dysfunction.

44 protein synthesis and promoting fibrosis and diastolic dysfunction.

45 may increase myocardial stiffness promoting diastolic dysfunction.

46 g, sympatho-vagal imbalance, arrhythmias and diastolic dysfunction.

47 , and 7 patients (29%) met the definition of diastolic dysfunction.

48 tion between diffuse myocardial fibrosis and diastolic dysfunction.

49 frequently associated with left ventricular diastolic dysfunction.

50 in both normal animals and a pig model with diastolic dysfunction.

51 ats (SHAM) and aortic-banded rats exhibiting diastolic dysfunction.

52 d by nondilated left or right ventricle with diastolic dysfunction.

53 r pressure overload, leading to fibrosis and diastolic dysfunction.

54 s is related to changes in right ventricular diastolic dysfunction.

55 239.9 vs. 576.7 +/- 472.9 events h(-1) ) and diastolic dysfunction (0.008 +/- 0.004 vs. 0.027 +/- 0.0

56 observed in 39% of patients), followed by LV diastolic dysfunction (16%) and LV systolic dysfunction

57 nd E/e' ratios; 2) their roles in diagnosing diastolic dysfunction; 3) prognostic implications of abn

58 hypertrophy (61% and 39%, respectively) and diastolic dysfunction (35% and 36%, respectively) than h

59 Nontransgenic TAC developed diastolic dysfunction (65% increase in E/A ratio), where

60 Myocardial steatosis predisposes to diastolic dysfunction, a heart failure precursor.

61 nt and high prevalence of LV hypertrophy and diastolic dysfunction; a subclinical systolic dysfunctio

62 ng pressure during exercise in patients with diastolic dysfunction after myocardial infarction.

63 sed left ventricular remodeling (hypertrophy/diastolic dysfunction), age, injury (high-sensitivity tr

64 and fibrosis biomarkers, and the severity of diastolic dysfunction all increased with severity of RVD

65 ventricular arrhythmic burden, and systolic/diastolic dysfunction (all p < 0.05).

66 e odds ratios (95% confidence intervals) for diastolic dysfunction among individuals with prediabetes

67 ertension, left ventricular hypertrophy, and diastolic dysfunction, among other cardiovascular disord

68 h are resistant to PKGIalpha oxidation, have diastolic dysfunction and a diminished ability to couple

69 re at year 0 was associated with both severe diastolic dysfunction and abnormal relaxation 5 years la

70 mposite endpoint in participants with severe diastolic dysfunction and abnormal relaxation were 4.3 (

71 tic cardiomyopathy is characterized by early diastolic dysfunction and adverse left ventricular (LV)

72 y play a central role in the pathogenesis of diastolic dysfunction and arrhythmia.

73 Finally, Myr improved diastolic dysfunction and attenuated histological abnorm

74 independent of blood pressure, by improving diastolic dysfunction and by modulating cardiac hypertro

75 dings may contribute to the left ventricular diastolic dysfunction and cardiac reserve function impai

76 r filling ratio (E/A), indicative of grade 1 diastolic dysfunction and emphasizing the importance of

77 he relationship between these indices and LV diastolic dysfunction and exertional symptoms has not be

78 ertension, left ventricular hypertrophy, and diastolic dysfunction and had higher myocardial natriure

79 essure overload and subsequently leads to LV diastolic dysfunction and heart failure over time.

80 )-related cardiomyopathy is characterized by diastolic dysfunction and hyperdynamic features.

81 pertension-induced cardiac injury, including diastolic dysfunction and impaired calcium handling.

82 lood transfusions; P<0.05 for both), whereas diastolic dysfunction and increased filling pressures we

83 odilation in obese ZSF1 rats that develop LV diastolic dysfunction and is used to model human HFpEF.

84 ntified subclinical disease features such as diastolic dysfunction and late gadolinium enhancement.

85 Diastolic dysfunction and left ventricular remodeling ar

86 Seventy patients with diastolic dysfunction and near normal left ventricular e

87 very of systolic function but persistence of diastolic dysfunction and no coronary aneurysms.

88 cular chamber levels showed that this causes diastolic dysfunction and other symptoms of heart failur

89 on, whereas deficient phosphorylation causes diastolic dysfunction and phenotypes resembling HFpEF.

90 left ventricular hypertrophy associated with diastolic dysfunction and premature death.

91 ks of a high-salt diet, 31 of 38 rats showed diastolic dysfunction and preserved ejection fraction al

92 The aging myopathy manifests itself with diastolic dysfunction and preserved ejection fraction.

93 herapies similarly improved left ventricular diastolic dysfunction and reduced left atrial diameter.

94 ctions, which are linked to left ventricular diastolic dysfunction and remodeling.

95 Left ventricular diastolic dysfunction and right ventricular dilatation a

96 Recurrent AF, was associated with increased diastolic dysfunction and vasopressor use and a greater

97 orubicin-injected fish developed ventricular diastolic dysfunction and worsening global cardiac funct

98 left ventricular ejection fraction >50%, and diastolic dysfunction) and 60 patients with stage B HF (

99 ontributes to the development of age-related diastolic dysfunction, and (2) initiation of late-life e

100 g for age, sex, left ventricular systolic or diastolic dysfunction, and aortic regurgitation.

101 was related to LV concentric remodelling and diastolic dysfunction, and associated with poorer clinic

102 layed decreased ventricular dimensions, mild diastolic dysfunction, and enhanced systolic function, w

103 II, left ventricular ejection fraction >50%, diastolic dysfunction, and exertional E/e' >13), excludi

104 HCM patients present with hypertrophy, diastolic dysfunction, and fibrosis, but there is no spe

105 e combined rates of LV systolic dysfunction, diastolic dysfunction, and heart failure.

106 EF exacerbates left ventricular hypertrophy, diastolic dysfunction, and HF.

107 ventricular abnormalities, such as low GLS, diastolic dysfunction, and hypertrophy (log-rank P<0.000

108 aracterized by left ventricular hypertrophy, diastolic dysfunction, and impaired myocardial strain, c

109 702 (1.5 mg/kg, IP for 8 weeks) prevented LV diastolic dysfunction, and in a crossover design augment

110 of myocardial substrate selection, reversed diastolic dysfunction, and normalized blood glucose leve

111 ardial fibrosis, abnormal perfusion reserve, diastolic dysfunction, and only rarely myocardial iron o

112 iated feature of SCA that is associated with diastolic dysfunction, anemia, and high NT-proBNP.

113 Increased left ventricular (LV) mass and diastolic dysfunction are associated with cardiovascular

114 ination for left ventricular hypertrophy and diastolic dysfunction as binary traits.

115 echocardiography disclosed left ventricular diastolic dysfunction as unexpected cardiogenic cause of

116 d 1.07-fold (1.03-1.11) higher prevalence of diastolic dysfunction as well as 1.3 (0.3-2.4) g/m(2) gr

117 tors of mortality or major morbidity: severe diastolic dysfunction, as evidenced by restrictive filli

118 pertrophy and fibrosis with normalization of diastolic dysfunction assessed by pressure-volume loop a

119 r, the estimated e' allowed prediction of LV diastolic dysfunction based on multiple age- and sex-adj

120 tive physician be alerted to the presence of diastolic dysfunction, be knowledgeable of the diastolic

121 ure; however, clinical tools for identifying diastolic dysfunction before echocardiography remain imp

122 mal Doppler E-wave filling patterns indicate diastolic dysfunction but are indistinguishable from the

123 therapy can be of value for the treatment of diastolic dysfunction, but there is a paucity of data ev

124 function (via echocardiography) demonstrated diastolic dysfunction by 2 weeks (20% increase in E/E'),

125 ial energy reserve is limited, contribute to diastolic dysfunction by recruiting cross-bridges, even

126 (b) elevate diastolic [Ca]i, contributing to diastolic dysfunction; (c) cause triggered arrhythmias;

127 3 loss did not affect survival, systolic and diastolic dysfunction, cardiac fibrosis, and cardiomyocy

128 opathy with similarities to HFpEF, including diastolic dysfunction, cardiac hypertrophy and fibrosis,

129 r afterload leads to myocardial hypertrophy, diastolic dysfunction, cellular remodelling and compromi

130 ncreased TAG accumulation, lipotoxicity, and diastolic dysfunction comparable to wild-type mice.

131 y-dependent left ventricular hypertrophy and diastolic dysfunction compared to sham mice.

132 D increment) had a stronger association with diastolic dysfunction compared with SBP.

133 ated with more global LV thickening and with diastolic dysfunction, compared to WES feeding alone.

134 Cardiac fibrosis is an underlying cause of diastolic dysfunction, contributing to heart failure.

135 of prospective risk markers associated with diastolic dysfunction could allow for targeted primary p

136 Additionally, absence of diastolic dysfunction criteria at echocardiography ruled

137 normalities result in progressive and severe diastolic dysfunction, culminating in heart failure.

138 hors aimed to assess the association between diastolic dysfunction (DD) and outcomes in patients with

139 Diastolic dysfunction (DD) is an independent predictor o

140 They contribute to myocardial diastolic dysfunction (DD) through collagen deposition o

141 eft ventricular systolic dysfunction (LVSD), diastolic dysfunction (DD), pulmonary arterial hypertens

142 f both sexes developed left ventricular (LV) diastolic dysfunction (DD), with 25% exhibiting grade II

143 erved ejection fraction is often preceded by diastolic dysfunction (DD).

144 oke volume (2.0%, P=0.002), left ventricular diastolic dysfunction (deceleration time [0.9%, P=0.03]

145 hic and clinical variables, left ventricular diastolic dysfunction defined as increased mitral E-to-s

146 corrected abnormal myocardial relaxation in diastolic dysfunction disease models in vitro and in viv

147 ps, patients with mild, moderate, and severe diastolic dysfunction displayed significantly reduced no

148 nt mechanism underlying cardiac fibrosis and diastolic dysfunction during increased renin-angiotensin

149 mal levels (0.018 +/- 0.002 s(-1)), reversed diastolic dysfunction (E/E' 14 +/- 1), and normalized bl

150 Twenty-three of them correlated with diastolic dysfunction (E/e') and 5 with left atrial volu

151 t banding induced concentric hypertrophy and diastolic dysfunction (early diastolic transmitral flow

152 y, increased lipid accumulation, exacerbated diastolic dysfunction (end diastolic pressure-volume rel

153 increased lipid accumulation and exacerbated diastolic dysfunction (end diastolic pressure-volume rel

154 In wild-type mice, cardiac hypertrophy, diastolic dysfunction (end diastolic pressure-volume rel

155 accumulation, and protected against cardiac diastolic dysfunction (end diastolic pressure-volume rel

156 with concentric remodelling and more severe diastolic dysfunction, especially in LF AS.

157 deformation indices with Doppler indices of diastolic dysfunction, functional capacity, biomarkers,

158 d ejection fraction and their correlation to diastolic dysfunction, functional class, pathophysiologi

159 ft ventricular dysfunction, left ventricular diastolic dysfunction grade II or III, right ventricular

160 astolic dysfunction, be knowledgeable of the diastolic dysfunction grading system and understand the

161 Participants with diastolic dysfunction had higher ECV (0.49 +/- 0.07 vs 0

162 s with concentric LV remodeling and isolated diastolic dysfunction had the poorest cognitive function

163 rmal predicted left atrial pressure (grade I diastolic dysfunction) had a measured pulmonary artery o

164 Heart failure (HF) with diastolic dysfunction has been attributed to increased m

165 ar exercise training ameliorates age-related diastolic dysfunction; however, the underlying mechanism

166 - and sex-matched hypertensive patients with diastolic dysfunction (hypertensive heart disease) but n

167 anding, 1.96x10(8)+/-6.8x10(7), P<0.001) and diastolic dysfunction improved simultaneously (E/E': ban

168 2% of participants and left ventricular (LV) diastolic dysfunction in 88%.

169 NCA) limits cardiomyocyte hypertrophy and LV diastolic dysfunction in a mouse model of diabetes melli

170 coronary perfusion are likely mechanisms of diastolic dysfunction in aged rats.

171 Late systolic load has been shown to cause diastolic dysfunction in animal models.

172 t ventricular hypertrophy (LVH) and systolic/diastolic dysfunction in asymptomatic patients with HF r

173 emporary measures of longitudinal strain and diastolic dysfunction in defining HF stages is unclear.

174 cardiomyopathy with severe left ventricular diastolic dysfunction in end-stage disease.

175 tex generation is an unreported mechanism of diastolic dysfunction in HCM and probably other causes o

176 Diastolic dysfunction in heart failure patients is evide

177 Although macitentan did not modulate diastolic dysfunction in HFpEF, it significantly reduced

178 rdial fibrosis in SCA mice, but the cause of diastolic dysfunction in humans with SCA is unknown.

179 is associated with incipient LV systolic and diastolic dysfunction in middle age.

180 of RV remodeling exist in obesity and (2) LV diastolic dysfunction in obesity is related to RV hypert

181 iew summarizes the underlying mechanisms for diastolic dysfunction in patients with mitral and aortic

182 However, it could contribute to diastolic dysfunction in patients with sepsis.

183 ing supracoronary aortic banding, we induced diastolic dysfunction in rats.

184 s a novel mechanism that appears to underlie diastolic dysfunction in SCA.

185 l myocardial fibrosis and is associated with diastolic dysfunction in sickle cell anemia (SCA).

186 ess promotes fibrosis and contributes to the diastolic dysfunction in the aging heart.

187 risk markers, and prognosis associated with diastolic dysfunction in the Coronary Artery Risk Develo

188 Ang 1-7 completely rescued the diastolic dysfunction in the db/db model.

189 ew focuses on recent findings on the role of diastolic dysfunction in the perioperative period and on

190 The precise mechanism of LV diastolic dysfunction in the presence of myocardial fibr

191 have added value to assess right ventricular diastolic dysfunction in this population.

192 fusion) resulted in more severe systolic and diastolic dysfunction in TIMP4(-/-) mice with enhanced i

193 hypertrophy and remodeling and systolic and diastolic dysfunction in transverse aortic constriction

194 ay contribute to increased susceptibility to diastolic dysfunction in women.

195 Diastolic dysfunction in young adults is associated with

196 correlated with echocardiographic indexes of diastolic dysfunction including a higher mitral E-wave z

197 cus on what is known concerning pre-clinical diastolic dysfunction, including definitions, staging, e

198 lvement, those with NAFLD had features of LV diastolic dysfunction, including higher E-to-e' ratio an

199 ABSTRACT: The risk for diastolic dysfunction increases with advancing age.

200 Right ventricular diastolic dysfunction influences outcomes in pulmonary a

201 Incorporation of longitudinal strain and diastolic dysfunction into the Stage B definition reclas

202 Age-related diastolic dysfunction is a major factor in the epidemic

203 Diastolic dysfunction is a poorly understood but clinica

204 Diastolic dysfunction is a prevalent and therapeutically

205 Diastolic dysfunction is a prominent feature of cardiac

206 Left ventricular diastolic dysfunction is an underestimated disease with

207 Diastolic dysfunction is associated with a high risk for

208 Diastolic dysfunction is associated with microscopic myo

209 Diastolic dysfunction is frequently seen after myocardia

210 Diastolic dysfunction is general to all idiopathic dilat

211 usion requirements, whereas left ventricular diastolic dysfunction is predominantly correlated with i

212 Left ventricular (LV) diastolic dysfunction is recognized as playing a major r

213 Although diastolic dysfunction is widely considered a key pathoph

214 mean 6 cm/s [SD 1.2] versus FGR 5.3 [1]) and diastolic dysfunction (isovolumic relaxation time: contr

215 Diastolic dysfunction, left atrial enlargement, and pulm

216 SAM-WD had developed HFpEF, characterized by diastolic dysfunction, left ventricular hypertrophy, lef

217 uction, left ventricular hypercontractility, diastolic dysfunction, left-atrial enlargement and left

218 normalities, including left ventricular (LV) diastolic dysfunction, longitudinal LV systolic dysfunct

219 Z value, +0.45 +/- 0.49, P < 0.001) and more diastolic dysfunction (lower E', Z value, -0.7 +/- 1.02,

220 er left ventricular ejection fraction, worse diastolic dysfunction, lower blood pressure and cardiac

221 ce ameliorated left ventricular hypertrophy, diastolic dysfunction, lung congestion, and myocardial o

222 larly in evaluation of left ventricular (LV) diastolic dysfunction (LVDD) and heart failure with pres

223 We investigated left ventricular diastolic dysfunction (LVDD) and its relationship with c

224 olic dysfunction (LVSD) and left ventricular diastolic dysfunction (LVDD).

225 nary venous pressure due to left ventricular diastolic dysfunction may contribute by exacerbating cap

226 and stroke volume (77 mL) were normal, while diastolic dysfunction (medial E/e', 16; deceleration tim

227 Pediatric PH patients exhibit LV diastolic dysfunction most consistent with impaired rela

228 PH patients had evidence of LV diastolic dysfunction, most consistent with impaired LV

229 ne the effect of chronic PDE9a inhibition, 2 diastolic dysfunction mouse models were studied: (1) TAC

230 s confirmed that the abnormalities including diastolic dysfunctions, myocardial fibrosis and metaboli

231 graphically proved mild, moderate, or severe diastolic dysfunction (n = 30, 44-73 years).

232 ortening this segment is sufficient to cause diastolic dysfunction need to be established.

233 Decline in FVC was associated with diastolic dysfunction (odds ratio, 3.39; 95% confidence

234 with E/A ratio (beta +/- SE: 0.12 +/- 0.04), diastolic dysfunction (odds ratio: 0.33; 95% confidence

235 erstitium, triggering fibrosis, systolic and diastolic dysfunction of stressed hearts.

236 ted, and the impact of left ventricular (LV) diastolic dysfunction on RV hypertrophy is unknown, we a

237 The influence of arterial afterload and diastolic dysfunction on the hemodynamic presentation of

238 predicted left atrial pressure (grade II/III diastolic dysfunction), only 17 (71%) had a pulmonary ar

239 lar resistance index was not associated with diastolic dysfunction or Ea/Ees.

240 nitions, or stricter inclusion criteria with diastolic dysfunction or left ventricular end-diastolic

241 ricular dilation or hypertrophy, systolic or diastolic dysfunction, or both, or various forms of cong

242 is and evidence of isolated left ventricular diastolic dysfunction (p < 0.05).

243 IPCAR was positively associated with grade I diastolic dysfunction (P < 0.050 for all logistic models

244 CV values (>/=0.40) were more likely to have diastolic dysfunction (P = .003) and increased left atri

245 rial volume (P = .002) and with the grade of diastolic dysfunction (P = .016).

246 This improvement in diastolic dysfunction parameters in aldosterone-infused

247 e effect may be partially mediated through a diastolic dysfunction pathway that includes left ventric

248 Pre-clinical diastolic dysfunction (PDD) has been broadly defined as

249 rmal (median from 54% to 64%; p < 0.001) but diastolic dysfunction persisted.

250 effects in the heart in vivo that lead to a diastolic dysfunction phenotype.

251 Diastolic dysfunction portends early mortality in SCA.

252 e sleep apnea, high-level physical training, diastolic dysfunction, predisposing gene variants, hyper

253 Diltiazem-HCl arrested diastolic dysfunction progression in R92W animals only,

254 x and includes left ventricular systolic and diastolic dysfunction, pulmonary vascular disease, endot

255 was inversely correlated to the severity of diastolic dysfunction (R = -0.61, P < .001).

256 th LV E/e' as an echocardiographic marker of diastolic dysfunction (r = 0.54, P < 0.05).

257 othesized that pediatric PH patients have LV diastolic dysfunction, related to adverse pulmonary hemo

258 Diastolic dysfunction represents a combination of impair

259 ADHF was defined as systolic or diastolic dysfunction requiring continuous vasoactive or

260 ies CKD and is perhaps best characterized as diastolic dysfunction seen in conjunction with left vent

261 e 27G TAC group had more severe systolic and diastolic dysfunction, severe cardiac fibrosis, and were

262 ad lower LS, greater dyssynchrony, and early diastolic dysfunction, supporting the notion that obesit

263 -deficient mice, however, showed exacerbated diastolic dysfunction, sustained elevation of membrane-t

264 y, smaller left atria, and less systolic and diastolic dysfunction than FG+ probands with HCM.

265 ure, seems to contribute to the systolic and diastolic dysfunction that characterizes the disease.

266 lar thickening at 4 weeks of age, as well as diastolic dysfunction that progressed with age, in Hyal2

267 ed cardiomyopathy with combined systolic and diastolic dysfunction-the absence of M-band titin to car

268 The latter affects left ventricular diastolic dysfunction through macrophage infiltration, r

269 expression contributes mainly to myocardial diastolic dysfunction through mitochondrial apoptosis, L

270 energetics, left ventricle hypertrophy, and diastolic dysfunction to recover.

271 As LV diastolic dysfunction typically precede heart failure sy

272 Diastolic dysfunction underlies HFpEF; therefore, elucid

273 More importantly, diastolic dysfunction usually improves with timely surgi

274 Furthermore, LV diastolic dysfunction was associated with increased LV f

275 Diastolic dysfunction was defined using Doppler and tiss

276 Diabetes mellitus-induced LV diastolic dysfunction was evident on echocardiography-de

277 diameter and left ventricular mass although diastolic dysfunction was more pronounced in OB/MS+ than

278 95% CI 2.07-10.9); however, left-ventricular diastolic dysfunction was not (P>0.05).

279 nts included in the primary analysis, severe diastolic dysfunction was present in 1.1% and abnormal r

280 Diastolic dysfunction was present in 26% of patients wit

281 Diastolic dysfunction was present in 66% of gradable par

282 Diastolic dysfunction was present in WES+DHA rats compar

283 rdial stiffness, consistent with upheld(101) diastolic dysfunction, was confirmed by an atomic force

284 ry capillary wedge pressure, consistent with diastolic dysfunction, was present in 15 patients (75%).

285 more, parameters reflecting left ventricular diastolic dysfunction were more pronounced in advanced N

286 left atrial dimension (19%; indicative of LV diastolic dysfunction) when compared with WT.

287 excess left ventricular (LV) hypertrophy and diastolic dysfunction; whether this occurs also in secon

288 c cardiomyopathy are cardiac hypertrophy and diastolic dysfunction, which lead to heart failure, espe

289 in db/db mice, but protected from myocardial diastolic dysfunction, while causing left ventricular ch

290 diabetic cardiac hypertrophy, fibrosis, and diastolic dysfunction, while preserving normal cardiac g

291 xpressing alpha-TM-D137L showed systolic and diastolic dysfunction with decreased myofilament Ca(2+)

292 sed passive stiffness is sufficient to cause diastolic dysfunction with exercise intolerance.

293 eas deficient cMyBP-C phosphorylation causes diastolic dysfunction with HFpEF in cMyBP-C(t3SA) mice.

294 ial (LA) enlargement and dysfunction, and LV diastolic dysfunction with preserved systolic function,

295 d by progressive left atrial enlargement and diastolic dysfunction with preserved systolic function.

296 re growth restricted and showed systolic and diastolic dysfunction, with an increase in cardiomyocyte

297 mpaired transmitral flow indicative of early diastolic dysfunction within 5 weeks.

298 has been broadly defined as left ventricular diastolic dysfunction without the diagnosis of congestiv

299 ral chemoreflex pathway in HFpEF exacerbates diastolic dysfunction, worsens sympatho-vagal imbalance

300 ter, mean limb lead QRS voltage, and grade 3 diastolic dysfunction yielded excellent discriminatory c